[HTML][HTML] Opioid analgesia and opioid-induced adverse effects: a review
AK Paul, CM Smith, M Rahmatullah, V Nissapatorn… - Pharmaceuticals, 2021 - mdpi.com
Opioids are widely used as therapeutic agents against moderate to severe acute and
chronic pain. Still, these classes of analgesic drugs have many potential limitations as they …
chronic pain. Still, these classes of analgesic drugs have many potential limitations as they …
[HTML][HTML] Pharmacological interventions for opioid-induced hyperalgesia: a scoping review of preclinical trials
ME Koponen, P Forget - Journal of Clinical Medicine, 2022 - mdpi.com
Background: Opioid analgesics are the most effective pharmacological agents for moderate
and severe pain. However, opioid use has several limitations such as opioid-induced …
and severe pain. However, opioid use has several limitations such as opioid-induced …
Mu opioid receptor in microglia contributes to morphine analgesic tolerance, hyperalgesia, and withdrawal in mice
D Reiss, T Maduna, H Maurin… - Journal of …, 2022 - Wiley Online Library
A major challenge in medicine is developing potent pain therapies without the adverse
effects of opiates. Neuroinflammation and in particular microglial activation have been …
effects of opiates. Neuroinflammation and in particular microglial activation have been …
OFP011 cyclic peptide as a multifunctional agonist for opioid/neuropeptide ff receptors with improved blood–brain barrier penetration
M Zhang, B Xu, N Li, R Zhang, Q Zhang… - ACS Chemical …, 2022 - ACS Publications
Mounting evidence indicates that the neuropeptide FF (NPFF) system is involved in the side
effects of opioid usage, including antinociceptive tolerance, hyperalgesia, abuse …
effects of opioid usage, including antinociceptive tolerance, hyperalgesia, abuse …
Neuropeptide FF and its receptors: therapeutic applications and ligand development
T Nguyen, J Marusich, JX Li… - Journal of medicinal …, 2020 - ACS Publications
The endogenous neuropeptide FF (NPFF) and its two cognate G protein-coupled receptors,
Neuropeptide FF Receptors 1 and 2 (NPFFR1 and NPFFR2), represent a relatively new …
Neuropeptide FF Receptors 1 and 2 (NPFFR1 and NPFFR2), represent a relatively new …
[HTML][HTML] Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors
L Kudla, R Przewlocki - Pharmacological Reports, 2021 - Springer
Opioid analgesics remain a gold standard for the treatment of moderate to severe pain.
However, their clinical utility is seriously limited by a range of adverse effects. Among them …
However, their clinical utility is seriously limited by a range of adverse effects. Among them …
Inhibition of Hsp90 in the spinal cord enhances the antinociceptive effects of morphine by activating an ERK-RSK pathway
Morphine and other opioids are commonly used to treat pain despite their numerous
adverse side effects. Modulating μ-opioid receptor (MOR) signaling is one way to potentially …
adverse side effects. Modulating μ-opioid receptor (MOR) signaling is one way to potentially …
Biodegradable amphipathic peptide hydrogels as extended-release system for opioid peptides
C Martin, M Dumitrascuta, M Mannes… - Journal of medicinal …, 2018 - ACS Publications
Chronic pain is currently treated with opioids that offer unsatisfactory long-term analgesia
and produce serious side effects. There is a clear need for alternative therapies. Herein …
and produce serious side effects. There is a clear need for alternative therapies. Herein …
The effect of combination of spiritual deep breathing exercise therapy on pain and anxiety in postoperative nonpatological orthopedic fracture patients.
Acute pain and anxiety at the severe level because of postoperative orthopedic fractures of
nonpathological causes high analgesic demand in patients. It causes a high risk of side …
nonpathological causes high analgesic demand in patients. It causes a high risk of side …
[HTML][HTML] Bifunctional peptidomimetic G protein-biased mu-opioid receptor agonist and neuropeptide FF receptor antagonist KGFF09 shows efficacy in visceral pain …
M Dumitrascuta, C Martin, S Ballet, M Spetea - Molecules, 2022 - mdpi.com
There is still an unmet clinical need to develop new pharmaceuticals for effective and safe
pain management. Current pharmacotherapy offers unsatisfactory solutions due to serious …
pain management. Current pharmacotherapy offers unsatisfactory solutions due to serious …